PTPN11 and head and neck squamous cell carcinoma: The unexpected lack of overlap of SHP2 inhibitor sensitivity and MEK inhibitor sensitivity in HNSCC led us to investigate whether other pathways in addition to the MEK pathway were being blocked by SHP099.